{"id":"tzp-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4594424","moleculeType":"Protein","molecularWeight":"500.68"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TZP-101 works by inhibiting the H+/K+ ATPase enzyme in the stomach lining, leading to a decrease in gastric acid production. This mechanism is similar to that of proton pump inhibitors (PPIs), but TZP-101 is designed to be more selective and have a faster onset of action.","oneSentence":"TZP-101 is a prodrug that is converted into its active form, which is a potent inhibitor of gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:53.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"}]},"trialDetails":[{"nctId":"NCT01710982","phase":"PHASE3","title":"Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection","status":"COMPLETED","sponsor":"Norgine","startDate":"2012-02","conditions":"Postoperative Ileus","enrollment":27},{"nctId":"NCT02993055","phase":"PHASE1","title":"A Study to Assess Ulimorelin in Healthy Subjects","status":"COMPLETED","sponsor":"Lyric Pharmaceuticals","startDate":"2015-01","conditions":"Healthy Subjects","enrollment":39},{"nctId":"NCT02784392","phase":"PHASE2","title":"Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial","status":"COMPLETED","sponsor":"Lyric Pharmaceuticals","startDate":"2016-10","conditions":"Enteral Feeding Intolerance (EFI)","enrollment":120},{"nctId":"NCT00612014","phase":"PHASE2","title":"Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2007-10","conditions":"Gastroparesis, Diabetes Mellitus","enrollment":78},{"nctId":"NCT00617552","phase":"PHASE2","title":"Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal Surgery","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2007-07","conditions":"Postoperative Ileus","enrollment":267},{"nctId":"NCT01405599","phase":"PHASE1","title":"Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects","status":"COMPLETED","sponsor":"Norgine","startDate":"2011-06","conditions":"Digestive System Disorders","enrollment":32},{"nctId":"NCT01405612","phase":"PHASE1","title":"Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers","status":"COMPLETED","sponsor":"Norgine","startDate":"2011-06","conditions":"Digestive System Disorders","enrollment":14},{"nctId":"NCT01668199","phase":"PHASE1","title":"A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101","status":"COMPLETED","sponsor":"Norgine","startDate":"2012-02","conditions":"Postoperative Ileus","enrollment":6},{"nctId":"NCT01296620","phase":"PHASE3","title":"Ulimorelin Study of Efficacy and Safety (ULISES 008)","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2011-02","conditions":"Gastrointestinal Dysmotility","enrollment":330},{"nctId":"NCT01285570","phase":"PHASE3","title":"Ulimorelin Study of Efficacy and Safety (ULISES 007)","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2011-01","conditions":"Gastrointestinal Dysmotility","enrollment":332},{"nctId":"NCT00639808","phase":"PHASE1","title":"Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2006-08","conditions":"Gastroparesis, Diabetes Mellitus","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ulimorelin HCl monohydrate (ulimorelin·HCl·H2O)"],"phase":"phase_3","status":"active","brandName":"TZP-101","genericName":"TZP-101","companyName":"Tranzyme, Inc.","companyId":"tranzyme-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TZP-101 is a prodrug that is converted into its active form, which is a potent inhibitor of gastric acid secretion. Used for Gastroesophageal reflux disease (GERD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}